TY - JOUR
T1 - Prognostic factors and morbidities after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer
AU - Touboul, Cyril
AU - Uzan, Catherine
AU - Mauguen, Audrey
AU - Gouy, Sebastien
AU - Rey, Annie
AU - Pautier, Patricia
AU - Lhommé, Catherine
AU - Duvillard, Pierre
AU - Haie-Meder, Christine
AU - Morice, Philippe
PY - 2010/4/1
Y1 - 2010/4/1
N2 - Purpose. The aim of this study was to evaluate the prognostic factors and morbidities of patients undergoing completion surgery for locally advanced-stage cervical cancer after initial chemoradiation therapy (CRT). Patients and Methods. Patients fulfilling the following inclusion criteria were studied: stage IB2-IVA cervical carcinoma, tumor initially confined to the pelvic cavity on conventional imaging, pelvic external radiation therapy with delivery of 45 Gy to the pelvic cavity and concomitant chemotherapy (cisplatin, 40 mg/m2 per week) followed by uterovaginal brachytherapy, and completion surgery after the end of radiation therapy including at least a hysterectomy. Results. One-hundred fifty patients treated in 1998-2007 fulfilled the inclusion criteria. Prognostic factors for overall survival in the multivariate analysis were the presence and level of nodal spread (positive pelvic nodes alone: hazard ratio [HR], 2.03; positive para-aortic nodes: HR, 5.46; p <.001) and the presence and size of residual disease (RD) in the cervix (p =.02). Thirty-seven (25%) patients had 55 postoperative complications. The risk for complications was higher with a radical hysterectomy (p =.04) and the presence of cervical RD (p =.01). Conclusion. In this series, the presence and size of RD and histologic nodal involvement were the strongest prognostic factors. Such results suggest that the survival of patients treated using CRT for locally advanced cervical cancer could potentially be enhanced by improving the rate of complete response in the irradiated area (cervix or pelvic nodes) and by initially detecting patients with para-aortic spread so that treatment could be adapted in such patients. The morbidity of completion surgery is high in this context.
AB - Purpose. The aim of this study was to evaluate the prognostic factors and morbidities of patients undergoing completion surgery for locally advanced-stage cervical cancer after initial chemoradiation therapy (CRT). Patients and Methods. Patients fulfilling the following inclusion criteria were studied: stage IB2-IVA cervical carcinoma, tumor initially confined to the pelvic cavity on conventional imaging, pelvic external radiation therapy with delivery of 45 Gy to the pelvic cavity and concomitant chemotherapy (cisplatin, 40 mg/m2 per week) followed by uterovaginal brachytherapy, and completion surgery after the end of radiation therapy including at least a hysterectomy. Results. One-hundred fifty patients treated in 1998-2007 fulfilled the inclusion criteria. Prognostic factors for overall survival in the multivariate analysis were the presence and level of nodal spread (positive pelvic nodes alone: hazard ratio [HR], 2.03; positive para-aortic nodes: HR, 5.46; p <.001) and the presence and size of residual disease (RD) in the cervix (p =.02). Thirty-seven (25%) patients had 55 postoperative complications. The risk for complications was higher with a radical hysterectomy (p =.04) and the presence of cervical RD (p =.01). Conclusion. In this series, the presence and size of RD and histologic nodal involvement were the strongest prognostic factors. Such results suggest that the survival of patients treated using CRT for locally advanced cervical cancer could potentially be enhanced by improving the rate of complete response in the irradiated area (cervix or pelvic nodes) and by initially detecting patients with para-aortic spread so that treatment could be adapted in such patients. The morbidity of completion surgery is high in this context.
KW - Chemoradiation therapy
KW - Completion surgery
KW - Locally advanced cervical cancer
KW - Morbidities
KW - Nodal involvement
KW - Prognostic factors
KW - Residual disease
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=77951746040&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2009-0295
DO - 10.1634/theoncologist.2009-0295
M3 - Article
C2 - 20332143
AN - SCOPUS:77951746040
SN - 1083-7159
VL - 15
SP - 405
EP - 415
JO - Oncologist
JF - Oncologist
IS - 4
ER -